Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) as Maintenance Treatment of HIV-1/Hepatitis B Virus (HBV)-Coinfected Patients: an Observational Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03425994
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:35.987087+00:00
Published At
2019-08-28T00:00:00+00:00
Record Updated At
2019-08-28
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Chronic Hepatitis B in HIV Patient", "Kidney Injury", "Bone Diseases"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2019-08-28"
protocolSection.identificationModule.nctId
"NCT03425994"
protocolSection.identificationModule.officialTitle
"Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) as Maintenance Treatment of HIV-1/Hepatitis B Virus (HBV)-Coinfected Patients: an Observational Study"
protocolSection.statusModule.overallStatus
"UNKNOWN"
protocolSection.designModule.phases
[]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Chronic Hepatitis B in HIV Patient (protocolSection.conditionsModule.conditions)
  • Kidney Injury (protocolSection.conditionsModule.conditions)
  • Bone Diseases (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.